hmpl-306
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2020 (NCT04272957)
Timeline
Indications
Mechanism of action
IDH1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07025018 | Phase 1 | Jul 15, 2025 | Fudan University, University of Washington |
| NCT06671873 | Phase 1 | Nov 26, 2024 | University of Washington |
| NCT06387069 | Phase 3 | Apr 26, 2024 | Peking University, University of Washington |
| NCT04764474 | Phase 1 | Feb 28, 2021 | Hutchison MediPharma |
| NCT04762602 | Phase 1 | Feb 28, 2021 | Hutchison MediPharma |
| NCT04272957 | Phase 1 | Mar 1, 2020 | Hutchison MediPharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hutchison MediPharma | For profit | 3 | 3 | 1 | 2020 |
| University of Washington | Academic/Hospital | 3 | 3 | 2 | 2024 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1